RxDoctor Payments Data

H Silverstein

Internal Medicine · Hartford, CTNPI 1033227392

Payments from drug & device makers

$2,306in general payments, 2019–2025

Across 80 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$659
  • Boehringer Ingelheim$525
  • Novo Nordisk$256
  • Bayer$192
  • Merck$179
  • Kowa Pharmaceuticals America, Inc.$148
  • plus $347 from 8 others

What the payments were for

  • Food & beverage$2,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,306 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$27,439
Medicare patients
439
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$78,674
XareltoRivaroxaban33$52,985
EliquisApixaban33$44,798
OzempicSemaglutide17$39,279
MounjaroTirzepatide19$34,785
FarxigaDapagliflozin Propanediol13$15,909
Nebivolol Hcl57$5,027
Ezetimibe140$2,637
Atorvastatin Calcium234$1,876
Colchicine20$1,772
Torsemide94$1,138
Spironolactone-HctzSpironolact/Hydrochlorothiazid31$902
Rosuvastatin Calcium86$860
Potassium Citrate ErPotassium Citrate12$824
Levothyroxine Sodium53$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$525$78,67451 claims
Johnson & JohnsonXarelto$659$52,98533 claims
PfizerEliquis$21$44,79833 claims
Novo NordiskOzempic$256$39,27917 claims
Lilly USA, LLCMounjaro$107$34,78519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →